- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Advanced NMR, GE may extend deadline
Advanced NMR and GE MedicalSystems are discussing an extension of their agreement to marketfast MRI systems. The two companies may push back the deadlinefor GE to sell 100 of Advanced NMR's InstaScan echo-planar imagingsystems to Dec. 31, 1995. Under
Advanced NMR and GE MedicalSystems are discussing an extension of their agreement to marketfast MRI systems. The two companies may push back the deadlinefor GE to sell 100 of Advanced NMR's InstaScan echo-planar imagingsystems to Dec. 31, 1995.
Under the terms of an agreement reached between the companieslast year, GE gained exclusive rights to InstaScan for two yearsin return for a guarantee to buy 100 InstaScan systems or otherAdvanced NMR products by December of this year (SCAN 3/10/93).
The agreement also included an option for GE to extend thecontract, while Advanced NMR retained the right to begin adaptingits technology to non-GE systems after June of this year.
Last month, Advanced NMR announced that it has extended theexercise date from June 15 to July 31 for GE to maintain exclusiverights to InstaScan. The move gives the companies more time tonegotiate an extension of their alliance, according to AdvancedNMR. A key issue in those discussions would be an extension ofGE's deadline for sales of InstaScan to December of 1995, accordingto the company.-
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
